Pancreatic Cancer Research

ResearcherJiangsu Province HospitalActive in the last 2 years

Jingjing Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6243-9815; OpenAlex author ID A5100369387. Sources: OpenAlex.

Their work

Papers
27 (first author 6, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
54
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: 5 papers · 2015: 1 paper · 2016: 2 papers · 2017: 6 papers · 2018: none · 2019: 3 papers · 2020: 3 papers · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 27

  1. Correction: A Yin-Yang 1/miR-30a regulatory circuit modulates autophagy in pancreatic cancer cells. First author DOI 10.1186/s12967-025-06581-5↗
  2. MiR-548t-5p regulates pancreatic ductal adenocarcinoma metastasis through an IL-33-dependent crosstalk between cancer cells and M2 macrophages. Last author DOI 10.1080/15384101.2024.2309026↗
  3. Suppressive effect of YY1-mediated RGS22 regulation on the proliferation, migration and invasion of pancreatic ductal adenocarcinoma. Last author DOI 10.3892/ol.2022.13577↗
  4. Roundabout homolog 1 inhibits proliferation via the YY1-ROBO1-CCNA2-CDK2 axis in human pancreatic cancer. Last author DOI 10.1038/s41388-021-01741-5↗
  5. Long noncoding RNA SOX2OT promotes pancreatic cancer cell migration and invasion through destabilizing FUS protein via ubiquitination. Last author DOI 10.1038/s41420-021-00640-8↗
  6. Long noncoding RNA SOX2OT promotes the proliferation of pancreatic cancer by binding to FUS. First author DOI 10.1002/ijc.32827↗
  7. The YY1/miR-548t-5p/CXCL11 signaling axis regulates cell proliferation and metastasis in human pancreatic cancer. Co-author DOI 10.1038/s41419-020-2475-3↗
  8. Optimization of internal reference genes for qPCR in human pancreatic cancer research. Co-author DOI 10.21037/tcr.2020.02.48↗
  9. The RNA m6A methyltransferase METTL3 promotes pancreatic cancer cell proliferation and invasion. Co-author DOI 10.1016/j.prp.2019.152666↗
  10. YY1 targets tubulin polymerisation-promoting protein to inhibit migration, invasion and angiogenesis in pancreatic cancer via p38/MAPK and PI3K/AKT pathways. Co-author DOI 10.1038/s41416-019-0604-5↗
  11. LncRNA BANCR Promotes Pancreatic Cancer Tumorigenesis via Modulating MiR-195-5p/Wnt/β-Catenin Signaling Pathway. Co-author DOI 10.1177/1533033819887962↗
  12. Yin Yang-1 suppresses pancreatic ductal adenocarcinoma cell proliferation and tumor growth by regulating SOX2OT-SOX2 axis. Co-author DOI 10.1016/j.canlet.2017.08.032↗
  13. A Yin-Yang 1/miR-30a regulatory circuit modulates autophagy in pancreatic cancer cells. First author DOI 10.1186/s12967-017-1308-3↗
  14. PEG10 overexpression induced by E2F-1 promotes cell proliferation, migration, and invasion in pancreatic cancer. Co-author DOI 10.1186/s13046-017-0500-x↗
  15. Association between ERCC2 Lys751Gln polymorphism and the risk of pancreatic cancer, especially among Asians: evidence from a meta-analysis. Co-author DOI 10.18632/oncotarget.15394↗
  16. The clinical value, regulatory mechanisms, and gene network of the cancer-testis gene STK31 in pancreatic cancer. Co-author DOI 10.18632/oncotarget.16814↗
  17. A novel messenger RNA signature as a prognostic biomarker for predicting relapse in pancreatic ductal adenocarcinoma. First author DOI 10.18632/oncotarget.22861↗
  18. Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer. Co-author DOI 10.18632/oncotarget.11953↗
  19. Yin Yang-1 increases apoptosis through Bax activation in pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.8654↗
  20. Overexpression of serine/threonine-protein kinase-1 in pancreatic cancer tissue: Serine/threonine-protein kinase-1 knockdown increases the chemosensitivity of … Co-author DOI 10.3892/mmr.2015.3434↗
  21. MUC4-induced nuclear translocation of β-catenin: a novel mechanism for growth, metastasis and angiogenesis in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2013.12.021↗
  22. Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction. First author DOI 10.1186/1471-2407-14-738↗
  23. Yin Yang-1 suppresses invasion and metastasis of pancreatic ductal adenocarcinoma by downregulating MMP10 in a MUC4/ErbB2/p38/MEF2C-dependent mechanism. Co-author DOI 10.1186/1476-4598-13-130↗
  24. Specific-detection of clinical samples, systematic functional investigations, and transcriptome analysis reveals that splice variant MUC4/Y contributes to the … First author DOI 10.1186/s12967-014-0309-8↗
  25. Upregulation of the splice variant MUC4/Y in the pancreatic cancer cell line MIA PaCa-2 potentiates proliferation and suppresses apoptosis: new insight into th… Co-author DOI 10.3892/or.2014.3113↗
  26. Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric … Co-author DOI 10.1186/1479-5876-11-262↗
  27. PP2A inhibitors induce apoptosis in pancreatic cancer cell line PANC-1 through persistent phosphorylation of IKKα and sustained activation of the NF-κB pathway. Co-author DOI 10.1016/j.canlet.2011.02.009↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yi Miao · 19 shared papers, 2011–2025 · strength 1.60
  2. Kuirong Jiang · 17 shared papers, 2013–2025 · strength 1.50
  3. Wanli Ge · 7 shared papers, 2019–2024 · strength 0.93
  4. Yunpeng Peng · 10 shared papers, 2013–2025 · strength 0.74
  5. Guodong Shi · 8 shared papers, 2017–2020 · strength 0.68
  6. Wentao Gao · 8 shared papers, 2013–2025 · strength 0.60
  7. Lingdong Meng · 5 shared papers, 2019–2022 · strength 0.59
  8. Xumin Huang · 5 shared papers, 2019–2021 · strength 0.53
  9. Lei Chen · 5 shared papers, 2017–2021 · strength 0.49
  10. Jishu Wei · 5 shared papers, 2014–2025 · strength 0.49
  11. Chuang Yang · 4 shared papers, 2016–2025 · strength 0.48
  12. Lingdi Yin · 4 shared papers, 2016–2025 · strength 0.45
  13. Xiong-Fei Zhang · 3 shared papers, 2017–2024 · strength 0.45
  14. Peng Shen · 4 shared papers, 2019–2021 · strength 0.42
  15. Qun Chen · 4 shared papers, 2019–2020 · strength 0.41
  16. Zipeng Lu · 6 shared papers, 2014–2019 · strength 0.40
  17. Zekuan Xu · 8 shared papers, 2011–2016 · strength 0.31
  18. Shouji Cao · 2 shared papers, 2021–2022 · strength 0.29
  19. Yan Wang · 2 shared papers, 2017–2024 · strength 0.29
  20. Hao Yuan · 3 shared papers, 2017–2020 · strength 0.25
  21. Kuirong Jiang · 3 shared papers, 2016–2020 · strength 0.23
  22. Yan Wang · 2 shared papers, 2017–2021 · strength 0.22
  23. Yi Zhu · 4 shared papers, 2014–2017 · strength 0.21
  24. Yi Miao · 3 shared papers, 2013–2019 · strength 0.21
  25. Qun Chen · 1 shared paper, 2022 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.